Wednesday, July 23, 2025

Worried About How Tariffs Will Affect Your Portfolio? Look for Stocks That Have 1 Super Characteristic.

How does this make you feel?


The stock market is experiencing volatility due to new tariff announcements, leading investors to seek ways to protect their portfolios. Identifying stocks with strong pricing power, such as Coca-Cola, Apple, Ferrari, Costco, and Netflix, can provide a buffer against the inflationary pressures tariffs may create. However, investors should consider the current valuation of these stocks and might benefit from a dollar-cost averaging strategy to mitigate risks while acquiring shares in resilient companies.

Full Article

Related Posts

Moody's (MCO) Q2 2025 Earnings Call Transcript

In Q2 2025, Moody's (NYSE:MCO) showed resilience by achieving revenue growth and increased adjusted operating margins despite a tough origination landscape and issuance declines. The company is focusing on private credit for growth, enhancing its role through strategic investments and partnerships, while also integrating GenAI and digital solutions to boost engagement and monetization opportunities. Want More Context? 🔎

Read more

Private Equity Groups Want a Piece of Your 401(k)

Private equity groups (PEGs) are gaining momentum following a provision in President Trump's new law that allows them to deduct more interest on debt through their acquisitions. This development positions PEGs, whose leaders support Trump, closer to accessing the lucrative $12 trillion 401(k) retirement market as they seek to restructure companies for profit within a few years. Want More Context? 🔎

Read more

Snowflake Stock Is on Fire. But Can the Momentum Last?

Snowflake (NYSE: SNOW), an AI and data platform specialist, has witnessed its stock rise nearly 40% year to date, significantly outperforming the S&P 500's 7% increase, driven by its focus on AI and rapid revenue growth. However, concerns arise as the company continues to report substantial quarterly losses despite a market capitalization of approximately $72 billion. Want More Context? 🔎

Read more

Medpace Beats Q2 Revenue Estimates

Medpace (NASDAQ:MEDP), a clinical contract research organization, reported strong Q2 2025 earnings, achieving GAAP revenue of $603.3 million and EPS of $3.10, surpassing estimates of $538.8 million and $2.98, respectively. The positive results led management to raise forecasts for the remainder of FY2025, reflecting ongoing operational success and top-line growth. Want More Context? 🔎

Read more

Welcome Back!

Login to your account below

Retrieve your password

Please enter your username or email address to reset your password.